News Releases
- August 29, 2022Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
- August 24, 2022Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
- August 8, 2022Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
- August 1, 2022Annovis Bio to Participate on Alzheimer's Association International Conference Panel
- July 14, 2022Annovis Bio to Present at the Alzheimer's Association International Conference
- July 7, 2022Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
- June 9, 2022Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
- December 14, 2021Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
- November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
- November 12, 2021Annovis Bio Presented at the 14th Clinical Trials on Alzheimer’s Disease Conference
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top